Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
This is Enzene Biosciences third biosimilar to be approved
The group now has 320 approvals and has so far filed over 400 ANDAs
Subscribe To Our Newsletter & Stay Updated